Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe

• Main Authors: Kui Huang (Author), Terri Madison (Author), Beatrice Wehler (Author), Marcello Tiseo (Author), Keith D. Wilner (Author), Jingping Mo (Author)
• Format: Book
• Published: Wiley, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Crizotinib (XALKORI®) is indicated for anaplastic lymphoma kinase‐positive and ROS1‐positive advanced non‐small cell lung cancer. This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cros...